The deal, valued at up to $150 million, will enable Bioniq’s science-driven, personalized supplementation platform to scale globally through Herbalife’s extensive infrastructure, which spans 95 markets.
“The future of health and wellness is becoming more personalized and informed by data,” said Stephan Gratziani, chief executive officer at US-based Herbalife. “By combining Bioniq’s personalized supplement technology with Pro2col and the power of our global distributor network, we are expanding our ability to deliver personalized wellness at global scale.”
From everyday shoppers to elite athletes
Launched in 2019 in London, Bioniq is an industry leader in offering personalized supplements based on personal questionnaires and blood test data.
“From day one, our mission at Bioniq has been to make health accessible, measurable, and truly personalized,” said Vadim Fedotov, founder and President of Bioniq. “As we scaled, it became clear that achieving this vision globally requires not only cutting-edge science and technology, but also the infrastructure to reach millions of people in a meaningful way.”
“Herbalife brings an unparalleled global platform, deep expertise in nutrition, and a powerful community-driven distribution model. By joining forces, we can accelerate our impact – taking our data-driven, individualized approach to health to a truly global standard.”
The business offers two product tiers; ‘Pro’ and ‘Go’. Bioniq Pro is positioned for high performers and health enthusiasts allowing users to upload bloodwork to gain a tailor-made daily supplement formula, as well as 1:1 nutrition consultations.
Bioniq Go utilizes the company’s same proprietary database to offer users a more accessible option, based on a questionnaire that prompts the AI algorithm to recommend users with a unique supplement blend based on their responses and previous users’ blood biomarker data.
The company’s growth has been fuelled in part by its ability to provide quantifiable before-and-after snapshots of users’ nutrient needs and optimization progress, making it appealing to elite athletes including footballing legend Cristiano Ronaldo, who is a global nutrition partner of Herbalife and Bioniq shareholder.
“Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level. As a long time Herbalife and Bioniq user, I’ve experienced first hand how a tailored approach to nutrition can help optimize performance,” said Ronaldo.
“I’m delighted to see Bioniq’s personalized supplements become part of Herbalife’s expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness and performance.”
Building a personalized nutrition portfolio
The latest deal will complement Herbalife’s prior acquisitions of Pro2col, a company specialized in building wellness plans from individuals’ unique data, as well as Link BioSciences, a nutritional and metabolic health company utilizing genomic and biochemical insights.
The combination of acquisitions aim to build a broad range of personalized nutritional supplements across multiple delivery formats.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. The $55 million purchase price will be paid over five years, including an initial payment of $10 million at closing. In addition, the transaction value includes up to $95 million of contingent payments based on future performance.
As part of the transaction, Herbalife also obtained the legal right to acquire Bioniq LAB, a separate platform focused on small molecules and peptides, providing the firm with flexibility to evaluate potential longer-term opportunities in this area.
Bioniq’s personalized nutritional supplements are expected to be offered through Herbalife independent distributors later this year for customers in select countries in Europe and the United States, with additional markets to follow.
